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ABSTRACT 
Nano medicine is a revolutionizing field that can benefit both diagnosis and treatment and contribute to a better quality of life. Despite the 
expected huge benefits, the potential risks on human health are significant as well. This thesis aims to defense a perspective that in case of 
nascent technologies, where the data are still emerging and scientific uncertainty prevails, risk governance should sustain the process of 
scientific knowledge by developing guidelines, codes of conduct and public information and provide a minimum level of safety acceptable to 
protect human health. Although Nano medicine is at an early stage of development some cautious measures should be taken that will provide 
regulatory mechanisms able to respond to the challenges posed by Nano medicine, establish a minimum level of safety but will also allow the 
further promotion of scientific knowledge. This multidisciplinary approach can contribute in adopting regulatory choices and tools that will 
help manage the risks, protect human health and promote scientific knowledge.  As the technologies are designed based on a clear 
understanding of a particular disease, disease specific oriented focus is required for the development of novel pharmaceuticals. In addition, it 
will be important to establish a case-by-case approach to clinical and regulatory evaluation of each Nano pharmaceutical. High priority should 
be given to enhancing communication and exchange of information among academia, industry and regulatory agencies encompassing  all facets 
of this multidisciplinary approach. 
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As for any other conventional medicine, the entire life cycle 
of Nano pharmaceuticals includes production, distribution, 
clinical administration, consumer safety (human body 
effects and side-effects), and waste disposal. While the 
clinical applications usually concern only the selected stages 
of the life cycle, toxicological effects may exist in all the 
stages. Both clinical applications and toxicology of Nano 
pharmaceuticals must be studied and examined 
comprehensively. 
When designing a clinical protocol for a Nano 
pharmaceutical there are new challenges. Clinical trials and 
epidemiology studies may be significantly different from 
those for conventional diagnostic and therapeutic agents. 
Early dialogue and collaboration between scientists, 
clinicians, toxicologists and regulatory authorities are 
increasingly recognized as one of the important issues to 
ensure rapid clinical uses of safe Nano pharmaceuticals. 
Nano scale objects, typically but not exclusively with 
dimensions smaller than 100 nm, smaller than 200 nm for 
ultrafiltrable range and smaller than 1000 nm for 
dendrimers, exhibit fundamentally different physical, 
chemical and biological properties from those of the 
corresponding mass materials. These distinctive properties, 
together with the Nano scale size which is in the same scale 
of the naturally occurring biomolecules, promise 
revolutionary potential applications in clinical practice. 
Nano medicines or Nano pharmaceuticals may therefore be 
defined as Nano scale material to be used for clinical 
diagnosis, treatment, and prevention of human disorders. 
Nano medicine application depends on the structures and 
mechanisms which are functional only on Nano scale-
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In particular, the following areas were considered: 
   Technology                                    Application 
 Nano pharmaceuticals                Cancer 
 – in current use or                           Antiviral agents  
entering routine use                        Arteriosclerosis  
in the short-term future                 Chronic lung diseases  
(within 5 years)                                Diabetes   
 Nano pharmaceuticals                Gene therapy 
 – with potential clinical                 Tissue engineering  
applications in the longer             Tissue/cell repair  
term future (10 years) 
Nano devices           Delivery of diagnostic and therapeutic  
                                      agents 
 
REGULATIONS & CLINICAL USES: 
There are very strict regulations and approval processes for 
any medicine (via regulatory agencies such as FDA, EMEA 
etc.) or any material proposed for human use. It must 
undergo rigorous toxicology studies as part of the regulatory 
approval process. However, the special properties of Nano-
objects that are only exhibited at the Nano scale suggest that 
Nano pharmaceuticals may also require a new array of 
toxicological and safety tests. It was agreed that new 
strategies in toxicology for Nano medicine must go hand-in-
hand with the development of Nano pharmaceuticals in 
order to ensure the safe yet swift introduction of Nano 
medicines to clinical use. 
 The toxicology of Nano pharmaceuticals, Nano imaging 
agents and nanomaterial’s used in device manufacture 
should be considered during their entire life cycle:  
• Stages of production/manufacture  
• Preclinical and clinical development (or for other uses e.g. 
veterinary) 
 • Consumer and staff safety 
 • Waste management/fate in environment. 
Although the Nano pharmaceuticals that have already 
entered routine clinical use have been rigorously tested with 
regard to safety, there have been comparatively few 
toxicological studies published on Nano pharmaceuticals. 
However, this issue needs to be explored, based on the large 
literature in the toxicology field describing the effects of 
nanoparticles, either present in the environment as 
pollutants or made as a result of the industrial production of 
non-medical and non-biological materials.  
Europe has considerable experience in the clinical 
development of Nano pharmaceuticals (particularly in 
cancer). Pre-clinical toxicology to ‘good laboratory practice’ 
(GLP) has assessed antibody drug conjugates, polymer-drug 
conjugates and nanoparticle-based chemotherapy. During 
the development of novel anticancer treatments there is 
always a careful evaluation of risk-benefit. 
 Since Europe has particular strengths in the research areas 
of toxicology of inhaled ambient or occupational fine and 
ultrafine particles there is an excellent opportunity to 
redress the current mismatch between studies on toxicology 
of nanomaterial’s and those involved in research and 
development of Nano medicine-related technologies. 
 As there seems to be enormous prospects for the 
application of nanotechnology in medicine, the European 
Nano medicine research community should act proactively 
to seize the opportunity to clearly define the ground rules 
for the related toxicological research, and the related clinical 
and industrial development of these important technologies. 
Apart from those Directives and Regulations, there are a 
variety of Guidelines and Principles, as Directive 
2001/20/EC for Good Clinical Practice – Clinical Trials of 
Medicinal Products, Directive 2003/94/EC for Good 
Manufacturing Practice for Medicinal Products and Directive 
2005/28/EC for Good Clinical Practice-investigational 
Medicinal Products. In order to complete the regulatory 
puzzle, attention should be paid to the fact that medicinal 
products for Advanced Therapy, Pediatric Use and Orphan 
are subject to different rules. Finally, other provisions are 
applicable to GMOs, Human Blood and Plasma as well as 
Human Tissue and Cells. Our analysis will focus on the 
medicinal products and medical devices regime. 
TOXICOLOGY ISSUES: 
There is an urgent need to improve the understanding of 
toxicological implications of Nano medicines in relation to 
the specific Nano scale properties currently being studied, in 
particular in relation to their proposed clinical use by 
susceptible patients. In addition, due consideration should 
be given to the potential environmental impact and there 
should be a safety assessment of all manufacturing 
processes. Risk-benefit assessment is needed in respect of 
both acute and chronic effects of Nano medicines in 
potentially pre-disposed patients – especially in relation to 
target disease. A shift from risk-assessment to proactive 
risk-management is considered essential at the earliest stage 
of the discovery, and then the development of new Nano 
medicines. 
REGULATORY GUIDELINES: 
As yet there are no regulatory authority guidelines specific 
to Nano medicine. As the number of Nano pharmaceuticals 
increases there is a need to review and define appropriate 
regulatory authority guidelines directed towards each new 
class of Nano medicine. It would be timely to produce ‘Good 
Clinical Practice’ (GCP) guidelines that may be applied to the 
clinical development of specific families of drug delivery 
systems or therapeutics. Some examples of well-established 
categories of pharmaceuticals involving Nano-objects are 
polymer protein, polymer-drug conjugates and nanoparticle 
associated chemotherapy. There may be specific clinical 
endpoints that are unique to these Nano medicines, and 
there may also be specific issues relating to good 
manufacturing practice (GMP) compliance. 
 Second generation Nano pharmaceuticals are already being, 
or will be, developed based on first generation systems. An 
integrated strategy will be the key for toxicological 
evaluation of new nanomaterial’s that are emerging. There is 
a need for preclinical and clinical test standardization and an 
evaluation of the environmental impact of these systems in 
the context of academic research and industrial 
development. On a case by case basis there is a need to 
define toxicokinetics, toxicogenomics, and toxicoproteomics. 
This field might be defined as ‘Toxiconanomics’. This 
research effort should be conducted by virtual networks of 
basic and applied scientists using existing expertise as a 
starting point. Industrial collaboration should be used to 
establish standard reference materials. 
The current regulatory system within Europe was not 
designed having Nano medicine in mind. As a consequence, 
one of the biggest challenges that regulators face nowadays 
is to adjust Nano medicine to the current regime. The 
existing legal background is established on European Union 
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legislation, legislation of other international instruments and 
national legislation. The general regulation is supported by a 
series of guidelines for the assessment, approval and control 
of the medicinal products within European Union.  
 The regulatory framework in the European Union under 
which the Nano medicine may fall is complex and multilevel. 
To be more specific, for Medicinal Products Regulation 
726/2004 on Authorization and Supervision of Medicinal 
Products for Human and Veterinary Use and Directive 
2001/83/EC on Medicinal Products for Human Use are 
applicable. For Medical Devices the normative framework 
consists of Directive 93/42/EEC concerning Medical Devices, 
Directive 90/385/EEC for Active Implantable Medical 
Devices and finally Directive 98/79/EC concerning In Vitro 
Medical Devices.   
 Apart from those Directives and Regulations, there are a 
variety of Guidelines and Principles, as Directive 
2001/20/EC for Good Clinical Practice – Clinical Trials of 
Medicinal Products, Directive 2003/94/EC for Good 
Manufacturing Practice for Medicinal Products and Directive 
2005/28/EC for Good Clinical Practice-investigational 
Medicinal Products. In order to complete the regulatory 
puzzle, attention should be paid to the fact that medicinal 
products for Advanced Therapy, Pediatric Use and Orphan 
are subject to different rules. Finally, other provisions are 
applicable to GMOs, Human Blood and Plasma as well as 
Human Tissue and Cells. Our analysis will focus on the 
medicinal products and medical devices regime. 
CONCLUSION: 
This Forward Look on Nano medicine has defined the remit 
of this emerging and important field. Nano medicine is 
clearly multidisciplinary and builds on the existing expertise 
in a large number of different scientific fields. European 
strengths have been identified, as have the short- and long-
term opportunities, and priorities for the development of 
Nano medicine-related technologies have been recognized. 
When applying nanotechnology to medical uses, it is 
particularly important to ensure thorough safety evaluation 
of any new technologies and also to review the likely 
environmental impact. In each specific case, careful risk-
benefit evaluation is required. Most importantly, an open 
and continuing dialogue is required to ensure all interested 
parties, including the general public, are well informed as to 
the ongoing technology developments in the field of Nano 
medicine. As much has been written in the popular press, 
quality information is required to assist policy makers and 
scientists to distinguish “science fact” from “science fiction’’. 
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